TheEdgeResearch
Home / Stocks / CSII

Cardiovascular Systems, Inc. (CSII)

NASDAQ Healthcare Medical - Devices
$20.00 ▲ +0.15%
Market Cap
$844.0M
Sector
Healthcare
Industry
Medical - Devices
Beta
0.74
52-Wk Range
12.255-20.0
CEO
Scott Raymond Ward MS
Country
US
Currency
USD

Cardiovascular Systems, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Saint Paul, MN, US. The stock last traded at $20.00, up 0.15% on the session, giving a market capitalisation of $844.0M. On trailing twelve-month figures it carries a trailing P/E of -21.28, a net margin of -15.6%. Its beta of 0.74 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-21.28
Price / Sales
3.57
Price / Book
3.14
EV / EBITDA
-23.71
Gross margin
73.1%
Operating margin
-15.2%
Net margin
-15.6%
Return on equity
Debt / equity
0.08
Current ratio
6.05
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
725
IPO date
2006-06-28
Headquarters
Saint Paul, MN, US
About Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc. (CSI) is a medical technology firm dedicated to the creation and commercialization of advanced therapeutic solutions for individuals suffering from peripheral and coronary artery diseases, serving markets both within the United States and internationally. For peripheral artery disease (PAD), CSI offers a range of catheter-based systems designed to treat various types of arterial plaque, including severely calcified deposits, in arteries located both above and below the knee. These systems aim to provide improved outcomes compared to conventional surgical, interventional, and pharmacological treatments. The company also provides supplementary peripheral support products. Regarding coronary artery disease (CAD), CSI supplies the Diamondback 360 Coronary Orbital Atherectomy System (OAS). This specialized device is engineered to aid in the successful placement of stents in CAD patients who present with heavily calcified coronary artery lesions and are deemed suitable candidates for percutaneous transluminal coronary angioplasty or stenting procedures. Furthermore, CSI manufactures and distributes essential procedural accessories such as guidewires, catheters, balloons, and embolic protection systems, along with other supporting products for its OAS technology. In a collaborative effort, Cardiovascular Systems, Inc. has partnered with Chansu Vascular Technologies, LLC, focusing on the development of innovative everolimus drug-coated balloons for both peripheral and coronary applications. Originally established in 1989 as Shturman Cardiology Systems, Inc., the company officially adopted its current name, Cardiovascular Systems, Inc., in January 2003. Its corporate headquarters are located in Saint Paul, Minnesota.

Comparable companies

Cardiovascular Systems, Inc. is most often compared with the following Healthcare names:

AORTAPENATRICDMOCMRXFNAHARPICPTPSTXSILK
More research on CSII
CSII technical analysis CSII TheEdge Score Compare against peers
Open full interactive analysis & DCF →